Abrocitinib Effective, Tolerated for Prurigo Nodularis, Chronic Pruritus

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, June 25, 2024 -- For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1 inhibitor, is effective and well tolerated, according to a study published online June 5 in JAMA Dermatology.

Shawn G. Kwatra, M.D., from the University of Maryland School of Medicine in Baltimore, and colleagues examined the efficacy and safety of 200-mg oral abrocitinib administered once daily in a phase 2, nonrandomized controlled trial involving 20 adult patients with moderate-to-severe PN or CPUO (10 with each). All 20 patients completed the 12-week treatment period, and 18 completed the four-week follow-up.

The researchers found that the Peak Pruritus Numerical Rating Scale (PP-NRS) scores decreased by 78.3 and 53.7 percent in PN and CPUO patients, respectively, by week 12. Eight of 10 patients with PN and six of 10 with CPUO achieved at least a 4-point improvement on the PP-NRS from baseline to week 12. Significant improvement in quality of life was experienced by both groups, as demonstrated by percentage change in Dermatology Life Quality Index scores (−53.2 and −49.0 percent for PN and CPUO, respectively). Acneiform eruption was the most common adverse event among patients (10 percent); there were no serious adverse events reported.

"Larger randomized, double-blind, placebo-controlled trials are needed to validate these findings, identify less common adverse effects, allow for subgroup analyses, and identify differences in systemic inflammatory markers between patients who respond to treatment and those who do not," the authors write.

One author disclosed ties to pharmaceutical companies, including Pfizer, which funded the trial and made and supplied the study drug.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-26 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords